Arine Inc. is a San Francisco-based company that develops a medication management platform aimed at improving patient health and quality of life. Founded in 2017, Arine utilizes a clinical learning and analytic response engine to deliver data-driven clinical services. The platform aggregates and analyzes clinical, social, and behavioral data to identify and address gaps in patient care, providing tailored medication recommendations and education to patients and their care teams. By focusing on evidence-based approaches, Arine optimizes medication use, enhances patient outcomes, and aims to reduce the overall cost of care. Their commitment to continuous monitoring and evaluation ensures timely follow-up and meaningful clinical service programs, guiding patients throughout their healthcare journey.
Electra Therapeutics is a clinical-stage biotechnology company focused on developing therapies that target signal regulatory proteins (SIRP) for treating immunological diseases and cancer. The company has one program in clinical development and two additional preclinical programs. Its lead product candidate, ELA026, is a monoclonal antibody designed to target SIRP on the surface of myeloid and T cells, effectively depleting pathological immune cells. ELA026 is currently being investigated for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition for which no approved treatment exists.
Asimily, Inc. develops a vertical specific distributed analytics software solution. The company offers healthcare specific management platform with non-invasive information technology and risk management for medical devices and vendors. The company's product portfolio of functionality includes managing the system of devices, helps predict the device posture across security and operational use cases, and ensures devices behave as expected. Asimily, Inc. was formerly known as Assimily, Inc. The company was incorporated in 2017 and is headquartered in Sunnyvale, California.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.
Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.
BrightInsight operates a digital health platform tailored for biopharma and medtech companies. Founded in 2017 and headquartered in San Jose, California, the company provides a global regulated platform designed for building, scaling, and maintaining digital health products and services. BrightInsight's Internet of Things (IoT) platform leverages software and services to capture, transmit, and analyze data from connected medical devices, digital therapeutics, and software as a medical device. By employing a quality management system, the platform supports regulated drugs and devices, enabling customers to enhance patient adherence and engagement through integrated data and actionable insights.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
BrightInsight operates a digital health platform tailored for biopharma and medtech companies. Founded in 2017 and headquartered in San Jose, California, the company provides a global regulated platform designed for building, scaling, and maintaining digital health products and services. BrightInsight's Internet of Things (IoT) platform leverages software and services to capture, transmit, and analyze data from connected medical devices, digital therapeutics, and software as a medical device. By employing a quality management system, the platform supports regulated drugs and devices, enabling customers to enhance patient adherence and engagement through integrated data and actionable insights.
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.
AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
BrightInsight operates a digital health platform tailored for biopharma and medtech companies. Founded in 2017 and headquartered in San Jose, California, the company provides a global regulated platform designed for building, scaling, and maintaining digital health products and services. BrightInsight's Internet of Things (IoT) platform leverages software and services to capture, transmit, and analyze data from connected medical devices, digital therapeutics, and software as a medical device. By employing a quality management system, the platform supports regulated drugs and devices, enabling customers to enhance patient adherence and engagement through integrated data and actionable insights.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Qlaris Bio, Inc., a biotechnology company, develops therapies for debilitating ophthalmic diseases. It offers QLS-101, a therapy to reduce intraocular pressure. Qlaris Bio, Inc. was founded in 2017 and is headquartered in Wellesley, Massachusetts.
Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Bellus Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. Additionally, the company is advancing KIACTA™, a novel treatment for AA amyloidosis and sarcoidosis, both rare diseases affecting renal and pulmonary functions, respectively. KIACTA™ is in the data review stage following a Phase 3 study. Bellus Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies in progress. Furthermore, the company has a research-stage project aimed at treating AL amyloidosis, a condition characterized by the accumulation of amyloid proteins in various organs. Bellus Health is dedicated to addressing unmet medical needs through its innovative drug development pipeline.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.
CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.
IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative drug treatments for Parkinson’s disease and related neurodegenerative disorders. The company's pipeline includes Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa clinical trials for dyskinesia, and IRL752, which has also completed Phase IIa trials targeting postural dysfunction. Additionally, IRLAB is advancing several research projects, including IRL942 and other compounds aimed at addressing the symptoms of Parkinson's disease and improving patient quality of life. Their ongoing efforts emphasize developing novel therapies that may substitute traditional treatments like levodopa and address the broader challenges associated with aging and neurodegeneration. Based in Gothenburg, Sweden, IRLAB is dedicated to enhancing therapeutic options within the field of brain disorders.
Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.
Kyruus, Inc. is a provider of web-based software solutions focused on optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, Kyruus offers a suite of analytically driven products designed to enhance the engagement, management, and performance of healthcare providers. Its solutions include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which provides administrators with tools to monitor and analyze physician performance. Additionally, the company offers Kyruus MDSeekyr for identifying high-value providers and Kyruus Insight Reports for evaluating physician network trends and performance. The ProviderMatch suite further aids hospitals in connecting patients with the most suitable providers, ensuring a seamless patient experience while aligning provider availability with patient demand. Through its proprietary data management platform, Kyruus leverages accurate data to facilitate effective appointments and enhance overall patient care.
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.
The company was founded in 2013 and is headquartered in Connecticut, United States.
Technology Will Save Us Ltd. specializes in developing DIY gadget kits and educational resources that encourage families, educators, and young people to engage with technology creatively. Founded in 2011 in London, the company offers a range of products, including a handheld games console, an electronic synthesizer, conductive dough, a DIY speaker kit, moisture sensors, and an open-source electronics platform. Their mission is to inspire the creative imagination of young people by providing hands-on technology experiences. With a team of 28 designers, educators, and engineers, the company focuses on creating award-winning kits and digital tools that facilitate learning through play. Technology Will Save Us has reached children in over 87 countries, offering its products through kiosks in the UK and online, while also collaborating with children to guide the design process based on extensive research.
Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, particularly opioid addiction. Founded in 2012 and based in Plymouth Meeting, Pennsylvania, Braeburn aims to address the significant challenges posed by opioid use disorder, a chronic condition that leads to structural and functional changes in the brain. The company's lead product is BRIXADI, an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe opioid use disorder. Braeburn is dedicated to advancing next-generation therapies that offer individualized dosing regimens and various delivery options, thereby providing effective solutions for patients, healthcare providers, and society at large.
Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.
AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.
Truveris, Inc. is a health information technology company based in New York that focuses on the management of pharmacy benefits and prescription drug costs. Founded in 2009, the company offers a comprehensive platform that includes solutions such as RxChoice, TruBid, and RxDash, which cater to various stakeholders in the prescription drug ecosystem, including pharmaceutical manufacturers, pharmacy benefit managers, and payers. Truveris leverages data-driven innovations to provide actionable insights that help clients navigate the complexities of pharmacy spending, ensure regulatory compliance, and validate claim payment accuracy. By offering tools for managing the entire pharmacy benefits lifecycle—from request for proposal to bill review—Truveris aims to enhance transparency and efficiency in the prescription drug market. The company's backing from multiple venture capital firms underscores its commitment to addressing rising costs and improving access to prescription medications.
Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drugs to improve the lives of cancer patients by tackling mechanisms of drug resistance that hinder the effectiveness of cancer therapies. The company's lead candidate, ripretinib, is aimed at treating gastrointestinal stromal tumors and is currently undergoing Phase I trials for various other cancers, including gliomas, melanoma, and non-small cell lung cancer. Deciphera is also advancing immunokinase inhibitors such as DCC-3014, which is in Phase I trials for tenosynovial giant cell tumors, and Rebastinib, currently in Phase Ib/II trials for solid tumors and in combination with chemotherapy. Additionally, the company is developing DCC-3116, a preclinical candidate targeting RAS mutant cancers. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera leverages its expertise in kinase inhibitors and maintains research capabilities near the University of Kansas to develop a diverse pipeline of small molecule drug candidates.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.
Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.
CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.
Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.
AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.
True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.
The company was founded in 2013 and is headquartered in Connecticut, United States.
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drugs to improve the lives of cancer patients by tackling mechanisms of drug resistance that hinder the effectiveness of cancer therapies. The company's lead candidate, ripretinib, is aimed at treating gastrointestinal stromal tumors and is currently undergoing Phase I trials for various other cancers, including gliomas, melanoma, and non-small cell lung cancer. Deciphera is also advancing immunokinase inhibitors such as DCC-3014, which is in Phase I trials for tenosynovial giant cell tumors, and Rebastinib, currently in Phase Ib/II trials for solid tumors and in combination with chemotherapy. Additionally, the company is developing DCC-3116, a preclinical candidate targeting RAS mutant cancers. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera leverages its expertise in kinase inhibitors and maintains research capabilities near the University of Kansas to develop a diverse pipeline of small molecule drug candidates.
Kyruus, Inc. is a provider of web-based software solutions focused on optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, Kyruus offers a suite of analytically driven products designed to enhance the engagement, management, and performance of healthcare providers. Its solutions include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which provides administrators with tools to monitor and analyze physician performance. Additionally, the company offers Kyruus MDSeekyr for identifying high-value providers and Kyruus Insight Reports for evaluating physician network trends and performance. The ProviderMatch suite further aids hospitals in connecting patients with the most suitable providers, ensuring a seamless patient experience while aligning provider availability with patient demand. Through its proprietary data management platform, Kyruus leverages accurate data to facilitate effective appointments and enhance overall patient care.
ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.
WaVe Life Sciences Ltd. is a clinical stage genetic medicine company focused on developing novel stereopure oligonucleotides through its proprietary PRISM platform. The company aims to address genetic defects by either reducing the expression of harmful proteins or converting dysfunctional mutant proteins into functional ones. It primarily concentrates on neurological disorders affecting the central and neuromuscular systems. WaVe Life Sciences has established research and collaboration agreements with major pharmaceutical companies to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The organization was established by leading scientists in the field of chemistry and life sciences, underscoring its commitment to innovative approaches in nucleic acid therapeutics.
Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancermore
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.
Edge Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for acute neurological conditions, particularly in hospital settings. Founded in 2009 and based in Berkeley Heights, New Jersey, the company aims to transform treatment paradigms for serious medical conditions with significant unmet needs. Its lead product candidate, EG-1962, is currently being evaluated in the Phase 3 NEWTON 2 study for the treatment of aneurysmal subarachnoid hemorrhage, a condition resulting from bleeding around the brain due to a ruptured aneurysm. Additionally, Edge is developing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aiming to prevent recurrent bleeding on the brain's surface. The company employs its proprietary Precisa platform to create polymer-based therapeutics that deliver treatment directly to the site of injury, minimizing impact on surrounding tissues.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.
QPID Health, Inc. is a healthcare IT software company that provides a health record intelligence platform designed to enhance the use of electronic health records (EHRs) in clinical settings. The company's flagship product, the Queriable Programmable Inference Dossier (QPID), enables healthcare institutions to generate clinician-directed queries, analytics, and reporting in real time, facilitating improved decision-making at the point of care. Developed initially at Massachusetts General Hospital, the QPID platform utilizes natural language processing and machine learning to deliver context-sensitive information from patient records, thereby increasing clinician productivity and supporting better patient outcomes. QPID Health is headquartered in Boston, Massachusetts, with an additional location in San Diego, California. The company aims to maximize the value of EHR investments and streamline quality reporting and clinical registry submissions, ultimately helping healthcare providers reduce costs and meet quality goals.
Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for rare and debilitating neuromuscular and neurological diseases in the United States. The company's flagship product, Firdapse, a proprietary form of amifampridine phosphate, is approved for treating Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. Catalyst is also conducting clinical trials for Firdapse in other conditions, including congenital myasthenic syndrome and anti-MuSK antibody positive myasthenia gravis. In addition to its proprietary treatments, Catalyst has established collaborations and license agreements for the development of other pharmaceutical products. Founded in 2002 and based in Coral Gables, Florida, the company was formerly known as Catalyst Pharmaceutical Partners, Inc. and rebranded in May 2015.
Karyopharm Therapeutics Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative drugs for cancer and other diseases. The company focuses on small molecule selective inhibitors of nuclear export (SINE) that target the exportin 1 protein, which plays a crucial role in the transport of proteins across the nuclear membrane. Its lead product, XPOVIO (selinexor), is designed for the treatment of heavily pretreated multiple myeloma. Karyopharm is advancing several clinical trials, including BOSTON in Phase 3 for multiple myeloma, STORM in Phase 2b, and SADAL in Phase 2b for diffuse large B-cell lymphoma. Additional trials target liposarcoma and endometrial cancer. The company also has ongoing preclinical and clinical programs for other investigational drugs like Eltanexor and KPT-9274. Collaborations with research entities, including PROMETRIKA and the National Cancer Institute, underscore its commitment to developing therapies for cancer and related conditions. Founded in 2008, Karyopharm is headquartered in Newton, Massachusetts.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Treato Ltd. operates Treato, provides social health patient intelligence solutions. The company offers health information platform that aggregates patient experiences from the Internet; and organizes them into usable insights for patients, healthcare professionals, pharma companies, and other healthcare organizations. Its Treato platform collects data from healthcare social media sites and forums; analyzes the information; and provides a window into patients’ thoughts and attitudes. The company also provides Treato Pharma, a brand intelligence service for pharma marketers and agencies to provide analytics and insights into patients’ thoughts and attitudes. Its Treato Pharma also interprets the patient voice, understands patient behaviors, gains competitive insights, extracts the right messages, expends effort into the right places, and engages in real time. Treato Ltd. was founded in 2008 and is based in Yehud, Israel.
iRhythm Technologies, Inc. is a digital healthcare company focused on improving the diagnosis and monitoring of cardiac arrhythmias in patients. Headquartered in San Francisco, the company provides innovative ambulatory electrocardiogram (ECG) monitoring solutions, primarily through its flagship product, the Zio service. This service utilizes a lightweight, wire-free, patch-based biosensor that patients can wear for up to 14 days, allowing for continuous heart monitoring. The Zio system integrates cloud-based data analytics and machine-learning capabilities to transform extensive heartbeat data into actionable clinical insights. By streamlining the diagnostic process, iRhythm aims to enhance patient health outcomes and reduce unnecessary healthcare expenses. Additionally, the company collaborates with Verily Life Sciences to develop advanced atrial fibrillation screening and monitoring products. Established in 2006, iRhythm continues to lead in the digital healthcare space by redefining cardiac arrhythmia diagnosis.
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.
ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.
Private Equity Round in 2012
Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.
Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, dedicated to the discovery and development of small-molecule antiviral therapeutics. Founded in 2006, the company primarily focuses on creating therapies for viral infections, with a significant emphasis on hepatitis C virus (HCV) and HIV. Its product portfolio features pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target the NS5A and NS5B proteins of HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be combined with other antiviral classes to address viral resistance, thus providing patients with effective treatment options against various hepatitis genotypes. The company has raised over $27 million from several investors to support its research and development efforts.
Access Closure, Inc. is a medical device company based in Mountain View, California, specializing in access site management products that facilitate vascular closure during interventional and diagnostic procedures. Founded in 2002, the company is known for its Mynx delivery system, a vascular closure device that employs a water-soluble, extravascular sealant. This innovative sealant expands within the tissue tract by absorbing blood and subcutaneous fluids, effectively sealing the arteriotomy. Access Closure aims to simplify the complex challenges associated with vascular closure, thereby enhancing patient outcomes during medical procedures.
Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.
IlluminOss Medical, Inc. is a medical device company specializing in the development of minimally invasive orthopedic systems for fracture repair and stabilization. Founded in 2007 and based in East Providence, Rhode Island, the company offers a unique technology that utilizes a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants. This innovative approach is particularly beneficial for treating osteoporotic and compromised bone, providing a fast and effective method for bone stabilization. The IlluminOss system is CE-marked and FDA-cleared for use in various anatomical sites, with additional indications currently under review. IlluminOss markets its products through distributors in several countries, including Austria, Germany, Israel, and the United Kingdom.
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of innovative medicines for cancer. Established in 2005, the company focuses on designing and developing orally-active small molecule drugs aimed at targeting specific molecular pathways. Its notable products include KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, designed for treating both hematological and solid tumors, and KA2507, an HDAC6 inhibitor intended for tumors expressing PD-L1. Karus Therapeutics aims to address unmet medical needs in oncology through its targeted therapeutic approaches.
Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.
Private Equity Round in 2012
Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).
Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.
Direct Flow Medical is a medical device company specializing in the development of transcatheter aortic tissue valve prostheses aimed at treating cardiac valve insufficiency. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, the company addresses a significant healthcare need, as only about 150,000 of these cases receive surgical treatment annually. The company's innovative technologies focus on improving patient outcomes and minimizing complications associated with heart valve replacement. By offering repeated assessments of hemodynamic performance prior to final implantation, Direct Flow Medical enables heart surgeons to perform valve replacements through less invasive procedures, thereby enhancing the safety and effectiveness of cardiac interventions.